Therapeutic antibodies: successes, limitations and hopes for the future
Tóm tắt
With more than 20 molecules in clinical use, monoclonal antibodies have finally come of age as therapeutics, generating a market value of $11 billion in 2004, expected to reach $26 billion by 2010. While delivering interesting results in the treatment of several major diseases including autoimmune, cardiovascular and infectious diseases, cancer and inflammation, clinical trials and research are generating a wealth of useful information, for instance about associations of clinical responses with Fc receptor polymorphisms and the infiltration and recruitment of effector cells into targeted tissues. Some functional limitations of therapeutic antibodies have come to light such as inadequate pharmacokinetics and tissue accessibility as well as impaired interactions with the immune system, and these deficiencies point to areas where additional research is needed. This review aims at giving an overview of the current state of the art and describes the most promising avenues that are being followed to create the next generation of antibody‐based therapeutic agents.
This article is part of a themed section on Vector Design and Drug Delivery. For a list of all articles in this section see the end of this paper, or visit:
Từ khóa
Tài liệu tham khảo
Adams GP, 2001, High affinity restricts the localization and tumor penetration of single‐chain fv antibody molecules, Cancer Res, 61, 4750
BatyD BeharG ChartierM PelegrinA TeillaudJL TeulonI(2006).Production of antibody formats and immunological applications of said formats. InWO/2006/064136.
Fujimori K, 1990, A modeling analysis of monoclonal antibody percolation through tumors: a binding‐site barrier, J Nucl Med, 31, 1191
Lo AS, 2008, Therapeutic Antibodies. Handbook of Experimental Pharmacology, Volume 181, 343
LonbergN(2008).Human monoclonal antibodies from transgenic mice. In:Y.Chernajovsky A.Nissim(Eds)Therapeutic Antibodies. Handbook of Experimental Pharmacology Volume 181 pp.69–97.Springer‐Verlag: Berlin Heidelberg.
Muller D, 2007, Recombinant bispecific antibodies for cellular cancer immunotherapy, Curr Opin Mol Ther, 9, 319
Shen J, 2008, Catumaxomab, a rat/murine hybrid trifunctional bispecific monoclonal antibody for the treatment of cancer, Curr Opin Mol Ther, 10, 273
Stocks M, 2006, Intracellular antibodies: a revolution waiting to happen?, Curr Opin Mol Ther, 8, 17